Skip to Main Content

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Conditions

Leukemia, not otherwise specified | Leukemia, other | Pediatrics

Phase II

What is the purpose of this trial?

This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.

  • Trial with
    Children's Oncology Group (COG)
  • Start Date
    05/27/2022
  • End Date
    05/11/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/12/2022
  • Study HIC
    #2000027013